Pliant Therapeutics Inc - Asset Resilience Ratio
Pliant Therapeutics Inc (PLRX) has an Asset Resilience Ratio of 70.16% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See PLRX working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Pliant Therapeutics Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see PLRX asset base.
Liquid Assets Composition Over Time
This chart breaks down Pliant Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read Pliant Therapeutics Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $133.22 Million | 70.16% |
| Total Liquid Assets | $133.22 Million | 70.16% |
Asset Resilience Insights
- Very High Liquidity: Pliant Therapeutics Inc maintains exceptional liquid asset reserves at 70.16% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Pliant Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Pliant Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Pliant Therapeutics Inc (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Pliant Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 64.60% | $145.50 Million | $225.23 Million | -7.08pp |
| 2024-12-31 | 71.68% | $284.54 Million | $396.95 Million | -12.48pp |
| 2023-12-31 | 84.16% | $431.01 Million | $512.15 Million | -0.70pp |
| 2022-12-31 | 84.85% | $297.50 Million | $350.61 Million | +17.53pp |
| 2021-12-31 | 67.32% | $148.93 Million | $221.22 Million | -9.15pp |
| 2020-12-31 | 76.48% | $226.01 Million | $295.53 Million | +62.23pp |
| 2019-12-31 | 14.25% | $16.97 Million | $119.06 Million | -- |
| 2018-12-31 | 0.00% | $0.00 | $66.53 Million | -- |
About Pliant Therapeutics Inc
Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform c… Read more